Literature DB >> 3154694

The combination of antianginal drugs: effects and indications.

P R Lichtlen1.   

Abstract

Today, three classes of drugs, all acting differently on the myocardium, the coronary circulation, and the peripheral circulation, that is, on the determinants for myocardial oxygen consumption (heart rate, contractility, and wall tension), are at the physician's disposition for anti-ischemic medical treatment: nitrates, beta-receptor blocking agents and Ca antagonists. All three drugs have been proven to exhibit a marked antianginal effect when given alone, as demonstrated both by an improvement in exercise performance as well as in perfusion and a significant decrease in symptomatic and silent ischemic episodes. Treatment should cover the total ischemic burden, which can be assessed today more accurately by Holter monitoring than with exercise tests alone. It has been shown in patients with stable angina that the majority of ischemic episodes are silent (over 75%); therefore, the question arose as to whether medical anti-ischemic treatment should aim at the prevention not only of symptomatic, but also of silent episodes. Furthermore, ischemia was revealed to be not only a marker for the presence of high-grade life-threatening obstructions, but also to have prognostic implications, not only in symptomatic, but also in asymptomatic episodes. In addition, ischemia can lead to life-threatening arrhythmia and irreversible myocardial damage, especially localized fibrosis. To what extent this is prevented by vigorous anti-ischemic treatment is still unanswered; however, as pathophysiologically symptomatic and asymptomatic ischemic episodes behave similarly, the latter should be included in treatment. The combinations of drugs, especially of nitrates and beta blockers, Ca antagonists and beta blockers, and also nitrates and Ca antagonists result in a further improvement in exercise performance and a reduction in ischemic episodes, allow the dose to be reduced, and minimize side effects. In addition, as is indicated from their hemodynamics, in special clinical situations, combinations might be preferable. Whether treatment should primarily reduce sympathetic drive or, rather, be directed towards vasodilation depends on the type of angina and the individual need. Hence, combining drugs in treating angina pectoris represents a true therapeutic challenge for the physician.

Entities:  

Mesh:

Year:  1988        PMID: 3154694     DOI: 10.1007/bf00054252

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  60 in total

1.  The role of left ventricular abnormalities in exercise-induced performance in patients with severe coronary artery disease.

Authors:  P R Lichtlen; P C Baumann; H Albert
Journal:  Cardiologia       Date:  1969

2.  Effect of intervals between doses on the development of tolerance to isosorbide dinitrate.

Authors:  J O Parker; B Farrell; K A Lahey; G Moe
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

3.  Drugs and the heart.

Authors:  L H Opie
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

4.  Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

5.  Silent myocardial ischemia: hemodynamic changes during dynamic exercise in patients with proven coronary artery disease despite absence of angina pectoris.

Authors:  H O Hirzel; R Leutwyler; H P Krayenbuehl
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

6.  Transient ST-segment depression as a marker of myocardial ischemia during daily life.

Authors:  J E Deanfield; M Shea; P Ribiero; C M de Landsheere; R A Wilson; P Horlock; A P Selwyn
Journal:  Am J Cardiol       Date:  1984-12-01       Impact factor: 2.778

7.  Prognosis of patients with coronary heart disease.

Authors:  W Steinbrunn; P R Lichtlen
Journal:  Hosp Pract (Off Ed)       Date:  1983-03

8.  Total ischemic burden: definition, mechanisms, and therapeutic implications.

Authors:  P F Cohn
Journal:  Am J Med       Date:  1986-10-20       Impact factor: 4.965

9.  Propranolol-verapamil versus propranolol-nifedipine in severe angina pectoris of effort: a randomized, double-blind, crossover study.

Authors:  M D Winniford; K L Fulton; J R Corbett; C H Croft; L D Hillis
Journal:  Am J Cardiol       Date:  1985-02-01       Impact factor: 2.778

10.  European coronary surgery study.

Authors:  E Varnauskas
Journal:  Z Kardiol       Date:  1985
View more
  1 in total

1.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.